@article {2372, title = {The Effects of Increasing Doses of Nigella Sativa and Conjugated Estrogen on Bone-Specific Alkaline Phosphatase (B-ALP), Procollagen Type 1 N-Terminal Propeptide (P1NP), Carboxy Terminal Crosslinked Telopeptide of Type 1 Collagen (CTX-1), and Osteoprotege}, journal = {Pharmacognosy Journal}, volume = {16}, year = {2024}, pages = {1-5}, type = {Research Article}, chapter = {1}, abstract = {

Introduction: Osteoporosis is characterized by decreased bone density, increasing the risk of fractures. Hormone therapy for post-menopausal osteoporosis has side effects, prompting the development of Nigella sativa (black cumin) as an alternative treatment. Objective: This study aims to determine the effect of administering Nigella sativa and conjugated estrogen as osteoporosis therapy in rats treated with bilateral oophorectomy, which have been verified as having osteoporosis based on bone biomarkers. Materials and Methods: This study involved 72 female Wistar rats divided into six groups: K+ (positive control), K- (negative control), P1 (receiving conjugated estrogen), P2 (receiving 100 mg/kg BW of Nigella sativa), P3 (receiving 200 mg/kg BW of Nigella sativa, and P4 (receiving 400 mg/kg BW of Nigella sativa. After inducing post-menopausal osteoporosis through bilateral oophorectomy, the treatment groups received therapy for 28 days. Bone biomarkers such as bone-specific alkaline phosphatase (bALP), procollagen type 1 n-terminal propeptide (P1NP), carboxy-terminal crosslinked telopeptide of type 1 collagen (CTX-1), and osteoprotegerin (OPG) were measured using ELISA. Results: The 400 mg/kg BW administration of Nigella sativa significantly increased bALP and P1NP levels, indicating higher osteoblast activity. At the same dose, Nigella sativa also increased OPG levels, suppressing osteoclastogenesis in bone resorption. However, 100-400 mg/kg BW/day of Nigella sativa did not reduce CTX-1 levels, nor did it inhibit osteoclasts in bone resorption. Estrogen conjugation also increased OPG levels but did not significantly affect bALP and P1NP levels. Conclusion: Nigella sativa at a dose of 400 mg/kg BW significantly increases osteoblast activity and OPG levels. Estrogen conjugation increases OPG levels but does not affect bALP and P1NP. Nigella sativa can potentially serve as an effective alternative therapy for osteoporosis through a mechanism different from conjugated estrogen.

}, keywords = {B-ALP, Bone biomarkers, Estrogen conjugation, Nigella sativa, Osteoporosis rats}, doi = {10.5530/pj.2024.16.175}, author = {Herpramanto Dwi Susetyo and Sri Ratna Dwiningsih and Widjiati and I Wayan Arsana} } @article {1932, title = {Relationship Histopathology Grading of Meningioma with the Use of Medroxyprogesterone Acetate (MPA) as A Hormonal Contraceptive}, journal = {Pharmacognosy Journal}, volume = {14}, year = {2022}, month = {January 2023}, pages = {938-941}, type = {Original Article }, chapter = {938}, abstract = {

Introduction: Meningioma is a common brain tumor with an incidence of more than 30\% of all primary brain tumors in adults. The incidence of meningiomas increases with increasing age, women suffer more from meningiomas with a ratio of 3:1. Meningiomas are known to have steroid receptors in the form of progesterone (88\%), estrogen (40\%), and androgen (40\%). Therefore, the use of hormonal therapy is suspected to affect the incidence and histopathological degree of meningioma. One of the widely used hormonal therapy is medroxyprogesterone acetate (MPA). However, there is not enough literature to explain the relationship between MPA and the incidence of meningioma. Objective: To identify the relationship between the duration of the use of Medroxyprogesterone acetate (MPA) hormonal contraceptives and the histopathological degree of meningioma. Methods: This study is an analytic observational with a retrospective design of meningiomas patients based on the duration of use of MPAtype hormonal contraception who performed surgery at Dr. Soetomo General Academic Hospital during the period January 2015 to December 2019. We determined the inclusion criteria for meningioma patients: a history of using MPA hormonal contraceptives or 3-month injectable contraceptives; and the control group: meningioma patients without a history of hormonal contraception. Results: There were 452 cases of meningioma and 101 patients met the inclusion criteria. Based on the results of statistical analysis, it was found that there was no difference relationship between the grade of meningioma and meningioma patients either using MPA or without using MPA. There was no difference in duration of use between the group using MPA \<10 years or more than 10 years with the non-hormonal control group on meningioma grading (p = 0.772). There was also no difference relationship between the group that did not use hormonal contraception and the MPA group on the age of the patient (p = 0.217), both using contraception for \<10 years and more than 10 years. Conclusion: There was no relationship found between histopathological degree of meningioma with the patients who use MPA contraceptives, both duration of use \<10 years and >=10 years compared with meningioma patients who do not use MPA contraception.

}, keywords = {Contraception, Grading, Hormonal contraceptive, Medroxyprogesterone acetate, Meningioma, MPA, Neoplasm., Progesterone}, doi = {10.5530/pj.2022.14.193}, author = {Shafhan Dustur and Joni Wahyuhadi and Budi Utomo and Muhammad Arifin Parenrengi and Abdul Hafid Bajamal and Sri Ratna Dwiningsih} }